BlossomHill Therapeutics

Reunited, a proven team advancing cancer treatments to overcome resistance

Jean Cui, Ph.D., Founder, Inventor, and Drug Designer: Dr. J. Jean Cui, Scientific Founder, President and CEO of BlossomHill Therapeutics, has become a household name due to her previous successes. Her BlossomHill team is building brand new cancer therapies from the ground up to address existing treatment limitations, including resistance, rather than building on existing therapies or science.
A Pandemic Idea Come to Fruition: BlossomHill’s pipeline was spawned while Jean was confined to her living room during the pandemic. The company flew under the radar when repotrectinib was approved last fall – one of three drugs invented by Jean now on the market. After securing $100M in a Series B financing, the company is advancing its oncology programs and continuing to expand its pipeline of oncology and autoimmune discovery programs.
Key Events in 2025: Progressing Phase 1 clinical trial investigating BH-30236-01, a multi-targeted CLK inhibitor, in relapsed or refractory adult acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS).